<DOC>
	<DOCNO>NCT01621490</DOCNO>
	<brief_summary>The purpose study evaluate pharmacodynamic change Nivolumab Nivolumab combination Ipilimumab treatment biomarkers measure peripheral blood tumor tissue subject advance melanoma ( unresectable advance )</brief_summary>
	<brief_title>PH 1 Biomarker Study Nivolumab Ipilimumab Nivolumab Combination With Ipilimumab Advanced Melanoma</brief_title>
	<detailed_description>Allocation : Part 1 2 : Single Arm study Part 3 4 : Randomized Controlled Trial Intervention Model : Part 1 2 : Single group : Single arm study Part 3 4 : Parallel : Participants assign one two group parallel duration study Minimum Age : Part 1 : 18 Part 2 , 3 4 : 16</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com Part 1 : Men woman &gt; 18 year Eastern Cooperative Oncology Group ( ECOG ) status = 0 1 Subjects unresectable Stage III IV melanoma either refractory intolerant , refuse standard therapy treatment metastatic melanoma Subject must histologic cytologic confirmation advance melanoma Subjects must least one measurable lesion baseline compute tomography ( CT ) magnetic resonance imaging ( MRI ) per Response Evaluation Criteria Solid Tumors ( RECIST ) 1.1 criteria Subjects must least 1 tumor site biopsied acceptable clinical risk must consent pre posttreatment biopsy Active progress brain metastasis Other concomitant malignancy ( exception per protocol ) Active history autoimmune disease Positive test human immunodeficiency virus ( HIV ) 1 &amp; 2 know acquire immunodeficiency syndrome ( AIDS ) History hepatitis Prior therapy antibody/drug target T cell coregulatory protein , include limited , antiPD1 , antiPDL1 , antiPDL2 , antiCD137 , antiOX40 , antiCD40 antibody . However , half patient must progress anti Cytotoxic T lymphocyteassociated antigen 4 ( antiCTLA4 ) monoclonal antibody therapy Part 2 , 3 4 : Inclusion Criteria Men woman &gt; 16 year Eastern Cooperative Oncology Group ( ECOG ) status = 0 1 Subjects unresectable Stage III IV melanoma either refractory intolerant , refuse standard therapy treatment metastatic melanoma Subjects must never receive antiCTLA4 therapy Subjects must histologic cytologic confirmation advance melanoma Subjects must least two measurable lesion baseline CT MRI per RECIST 1.1 criterion Subjects must least 1 tumor site biopsied acceptable clinical risk must consent pre posttreatment biopsy Subjects Part 4 must brain metastasis Exclusion Criteria Active progress brain metastasis ( except Part 4 subject ) Other concomitant malignancy ( exception per protocol ) Active history autoimmune disease Positive test HIV 1 &amp; 2 known AIDS History hepatitis Prior therapy antibody/drug target T cell coregulatory protein , include limited , antiPD1 , antiPDL1 , antiPDL2 , antiCD137 , antiOX40 , antiCD40 antibody</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>